From exam to action plan in 30 minutes
Click each step. The body on the left shows what Kinexa sees and infers at that point in the journey.
One patient, two AIs
Clinical observation: slight limp, reduced hip flexion. Compare what a standard AI returns with what Kinexa returns.
Example taken from the Kinexa investor file, for illustration. Device under development, not CE/FDA cleared, and not a substitute for medical advice.
Switch features on, see who is ready to buy
Each switch adds a product feature. Each target's bar shows the share of its needs covered. Indicative reading, built from the investor file.
Kinexa vs Hinge Health and Sword Health
| Criterion | Hinge / Sword | Kinexa |
|---|---|---|
| When it intervenes | Reactive: pain already exists (red ocean) | Proactive: subclinical conditions (blue ocean) |
| Technology | Computer vision plus costly wearable sensors | Pure smartphone vision (308 points) plus LLM |
| Diagnosis | Self-reporting, black-box AI | Root cause, white-box Bayesian networks |
| Hardware to ship | Yes | No, 100% smartphone |
| Clinical base | Generic protocols | 20 years of AP-HP expertise, 100,000+ digitised cases |
| Scientific backing | Standard clinical studies | CNRS Gold Medal 2025 (S. Mallat), ENS, MIT |
See Kinexa in action
The hip case in 90 seconds.
Kinexa against the incumbents, in 9 minutes.
Four patient profiles
Frail seniors, working people with MSK disorders, post-hospital patients, autonomous seniors. Pick a profile.
Five sales channels, five speeds
Set the weight of each channel in your go-to-market plan. The more slow channels you target (insurers), the later the first revenue arrives. This shift feeds the financial model.
Channel weights
Sales cycle length (months)
Each bar runs from the shortest to the longest cycle. Thickness follows the weight you set.
A demographic wave
Sources cited in the investor file: Grand View Research, WHO, Meditechinsights, Sacra, Upswing Health, PitchBook.
What does your ticket return, and when?
Everything is adjustable. Starting values come from the investor file plan: €1M revenue in year 1, €16M in year 5.
What is your stake worth if you exit in year N?
Exit proceeds year by year, under your assumptions. The orange dot is the chosen horizon.
4 years or 5 years: compare two horizons
Same assumptions, only the exit date changes.
Multiple on invested capital (MOIC) by horizon
Annual return (IRR) by horizon
Click a bar to set the horizon.
Revenue and operating profit
Hover (or tap) a year for details.
Your ownership, round after round
Each funding round dilutes your stake. Bars show the percentage you hold.
What if the assumptions change?
Multiple on your ticket at the chosen horizon, by sale price and share of the plan achieved. Click a cell to apply it.
Year by year
What your ticket funds, and what could go wrong
A summary of the Kinexa deck. The full detail stays in the complete presentation.
Use of the €250k (bridge round)
Roadmap
Risks and mitigations
| Risk | Mitigation | Fallback |
|---|---|---|
| AI accuracy below 90% | AP-HP validation on 50 patients, review by 3 independent physicians, explainable Bayesian networks | Pivot to a decision-support tool |
| Limited senior adoption | Voice interface, large buttons, 3D guidance, 65+ user tests from month 4 | Optional human coaching |
| CE / FDA delays (24 to 36 months) | Wellness positioning at first, CE first (12 to 18 months) | B2B revenue from year 1 |
| Long B2B sales cycles | Stauble, US primary care and care homes (3 to 6 months) | B2C in parallel |
| Key-person risk | Digitised expertise, documented protocols, junior physician trained in year 2 | €500k key-man insurance |
The team
20 years of expertise, former AP-HP head of department, 100,000+ digitised cases.
Healthtrax co-founder. Letter of intent signed.
Collège de France, CNRS Gold Medal 2025.
Inria, ENS-PSL, French Academy of Sciences.
SiPearl, president of MIT Alumni France.
Quantitative finance, MIT and London Business School.
Next steps, 6 to 8 weeks
Figures come from the company's own deck and have not been independently verified. The AP-HP study has not yet been carried out.
What prevention returns to a payer
Set the assumptions for your portfolio. Starting values are assumptions: they help read the mechanics, not promise a result. The break-even point does not depend on optimism.
Return sensitivity
by share avoided
Proposed pilot
- Duration: 6 months, 200 to 500 people.
- Measures: uptake, falls or care use, satisfaction.
- Compared with a control group or the portfolio's history.
- Decision at the end: continue, adjust or stop.
What reassures
- European hosting possible and GDPR compliance by design.
- Explainable reasoning: every conclusion is traceable (Bayesian networks).
- Regulatory status stated plainly: CE marking and FDA not obtained.
- Clinical validation planned at AP-HP on 50 patients, not yet carried out.
Sources
- Healthcare IT News, 27 Nov 2023: Upswing Health, company-reported results
- Kinexa investor dossier: $50 per user per month price, €5 to 10k per site, regulatory status, AP-HP study
These calculations illustrate a mechanism. They are neither a promise of results nor advice.